StockData

BioHarvest Sciences vs Lexicon Pharmaceuticals

BHST and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BHST and LXRX compare

BioHarvest Sciences grew revenue faster over the last twelve months (37.0% versus −29.0% for Lexicon Pharmaceuticals).

BioHarvest Sciences keeps more of each dollar of sales as profit, with a net margin of −32.3% compared with −147% at Lexicon Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBHSTLXRX
Size and price
Market cap–$792M
Share price$1.22$1.78
Change, 1 year−83.1%19.5%
Change, 5 years−88.2%−62.4%
Beta (5Y)1.770.01
Employees–81
StockData Score
Total score55
Valuation score00
Growth score2 (better)1
Performance score12 (better)
Health score22
Dividend score00
Valuation
P/S–19.1×
P/B–4.5×
Fair value–$0.950
Margin of safety–−87.4%
Growth
Revenue growth (TTM)37.0% (better)−29.0%
Revenue growth, 5Y average–15.7%
Profitability
Gross margin59.3%99.1% (better)
Operating margin−16.2% (better)−131%
Net margin−32.3% (better)−147%
FCF margin−27.8%–
Return on equity−83.2%−40.2% (better)
Return on invested capital−163% (better)−163%
Financial health
Debt / equity0.01 (better)0.29
Current ratio3.9713.37 (better)
Altman Z-score–−4.87
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions7.4%81.9%
Held by insiders0.00%–
Insider net buying, 12 months–$2.8M
Short interest, % of float0.33%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.